Clinical Trial of AMG510 in Stage III Unresectable NSCLC KRAS p.G12C Patients and Ineligible for Chemo-radiotherapy

PHASE2RecruitingINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

March 21, 2022

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2028

Conditions
Non-small Cell Lung Cancer Stage IIIKRAS P.G12C
Interventions
DRUG

Sotorasib

AMG510 (Sotorasib) is small molecule that specifically and irreversibly inhibits the KRAS-G12C mutant protein. AMG510 (Sotorasib) finished product is presented as tablets containing 120mg and will be packaged in bottles of 120 tablets.

Trial Locations (20)

15006

RECRUITING

Hospitalario Universitario A Coruña, A Coruña

17007

RECRUITING

ICO Girona, Hospital Josep Trueta, Girona

18016

RECRUITING

Hospital Clínico San Cecilio De Granada, Granada

23007

RECRUITING

Complejo Hospitalario De Jaén, Jaén

27003

RECRUITING

Hospital Universitario Lucus Augusti, Lugo

28040

RECRUITING

Hospital Clínico San Carlos, Madrid

RECRUITING

Hospital Universitario Fundación Jiménez Díaz, Madrid

28222

RECRUITING

Hospital Universitario Puerta de Hierro, Majadahonda

28911

RECRUITING

Hospital Universitario Severo Ochoa, Leganés

41013

RECRUITING

Hospital Universitario Virgen Del Rocio, Seville

46014

RECRUITING

Hospital General Universitario De Valencia, Valencia

46026

RECRUITING

Hospital Universitario La Fe, Valencia

48013

RECRUITING

Hospital De Basurto, Bilbao

08916

RECRUITING

ICO Badalona, Hospital Germans Trias i Pujol, Badalona

07120

RECRUITING

Hospital de Son Espases, Palma de Mallorca

03010

RECRUITING

Hospital General Universitario de Alicante, Alicante

08028

RECRUITING

Hospital Universitari Quiron Dexeus, Barcelona

08035

RECRUITING

Hospital Universitari Vall d' Hebron, Barcelona

08208

RECRUITING

Hospital Parc Taulí, Barcelona

07198

RECRUITING

Hospital Universitari Son Llatzer, Palma de Mallorca

All Listed Sponsors
lead

Fundación GECP

OTHER